OncoMatch/Clinical Trials/NCT02843945
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Is NCT02843945 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Directional Brachytherapy Source Implant for pancreatic cancer.
Treatment: Directional Brachytherapy Source Implant — Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Prior therapy
Must have received: chemoradiation (gemcitabine, nab-paclitaxel, FOLFIRINOX, capecitabine, 5-fluorouracil) — neoadjuvant
Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery); Chemotherapy was administered for 2-6 cycles with any combination of the following agents: Gemcitabine + nb-paclitaxel, FOLFIRINOX; Neoadjuvant Chemoradiation was administered as IMRT or 3DCRT (up to 56 Gy), or SBRT (up to 36 Gy) with Pre-operative External beam dose (NCCN) up to 56 Gy (1.8-2.0 Gy per fractions) with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil
Cannot have received: radiation therapy
Exception: to the region for separate cancer
No prior radiation therapy to the region for separate cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tampa General Hospital · Tampa, Florida
- Rush University Cancer Center · Chicago, Illinois
- Advocate Christ Medical Center · Oak Lawn, Illinois
- University Medical Center LSU · New Orleans, Louisiana
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify